Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399439 | 0.91 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1POLB | |
| SCHEMBL1399472 | 0.80 | NPC1 (0.40) | SLC6A2SLC6A4SLC6A3HPGDNPC1 | |
| SCHEMBL1570686 | 0.76 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3NPC1CYP2D6 | |
| SCHEMBL1399230 | 0.75 | IFNAR1 (0.62) | SLC6A2SLC6A4SLC6A3MEN1POLB | |
| SCHEMBL1399336 | 0.75 | IFNAR1 (0.62) | SLC6A2SLC6A4SLC6A3MEN1POLB | |
| SCHEMBL16644108 | 0.74 | SMN1; SMN2 (0.57) | SLC6A2SLC6A4SLC6A3MEN1POLB | |
| SCHEMBL11753290 | 0.74 | SLC6A4 (0.69) | SLC6A2SLC6A4SLC6A3MEN1POLB | |
| SCHEMBL1571426 | 0.73 | IMPDH2 (0.49) | SLC6A2SLC6A4SLC6A3NPC1GFER | |
| SCHEMBL12629158 | 0.72 | SMN1; SMN2 (0.55) | SLC6A2SLC6A4SLC6A3MEN1POLB | |
| SCHEMBL13912377 | 0.72 | SMN1; SMN2 (0.55) | SLC6A2SLC6A4SLC6A3MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1860100-B1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | LUNDBECK & CO AS H (DK) | 2011-03-02 | — | — | EP | claimed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | claimed |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | claimed |
| EP-1860100-A2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. Lundbeck A/S (DK) | 2007-11-28 | — | — | EP | claimed |
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1860100-B1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | LUNDBECK & CO AS H (DK) | 2011-03-02 | — | — | EP | disclosed |
| US-7737171-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7737170-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7652150-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIs | H. LUNDBECK A/S (DK) | 2010-01-26 | — | — | US | disclosed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | disclosed |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-07-24 | — | — | US | disclosed |
| EP-1860100-A2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. Lundbeck A/S (DK) | 2007-11-28 | — | — | EP | disclosed |
| EP-1701940-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H.Lundbeck A/S (DK) | 2006-09-20 | — | — | EP | disclosed |
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| WO-2005061455-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H. LUNDBECK A/S (DK) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | TPH1, TPH2, HTR2B | SLC6A2 11/4885SLC6A4 10/4885SLC6A3 25/4885 |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | SLC6A2 11/4885SLC6A4 12/4885SLC6A3 26/4885 |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | SLC6A2 11/4885SLC6A4 12/4885SLC6A3 26/4885 |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | TPH2, TPH1, HTR2B | SLC6A2 11/4885SLC6A4 10/4885SLC6A3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.